...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >The Italian External Quality Control Programme for cystic fibrosis molecular diagnosis: 4 years of activity.
【24h】

The Italian External Quality Control Programme for cystic fibrosis molecular diagnosis: 4 years of activity.

机译:用于囊性纤维化分子诊断的意大利外部质量控制计划:开展活动已有4年。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The Italian External Quality Control Programme for cystic fibrosis molecular diagnosis started in 2001; public laboratories distributed throughout Italy participated on a voluntary basis. METHODS: The Italian Public Health Institute (Istituto Superiore di Sanita) sent six validated DNA samples to participating laboratories: technical and clinical information was provided for each sample. Laboratories were required to analyse all six samples. For each sample the laboratories had to provide the results (including raw data) and a report of molecular analysis within 2 months using current methods and nomenclature. Raw data and reports were evaluated by a Steering Committee and their comments were sent to each laboratory. RESULTS: Genotyping results indicated a general good level of quality for all laboratories, i.e., approximately 1% of alleles were incorrectly assigned each year due to analytical (45%) and misinterpretation (45%) errors. During the first 2 years, more than 70% of laboratories did not test for some regional Italian mutations. Commercial kits for reverse dot-blot and oligonucleotide ligation assay PCR were used to detect mutations by 52.8% and 29.5%, respectively, of the participating laboratories. Reporting of results was still inadequate; in 2004 a model for the written report was introduced, but not all laboratories used it. CONCLUSIONS: Our data show that few genotyping errors were made by laboratories and were principally due to misinterpretation and analytical reasons. However, reports are still inadequate and it will be interesting to evaluate the introduction of the reporting model in future years.
机译:背景:意大利关于囊肿性纤维化分子诊断的外部质量控制计划始于2001年。意大利各地分布的公共实验室是自愿参加的。方法:意大利公共卫生研究所(Istituto Superiore di Sanita)向参与实验室发送了六个经过验证的DNA样本:每个样本均提供了技术和临床信息。要求实验室分析所有六个样品。对于每个样品,实验室必须使用当前的方法和命名法在2个月内提供结果(包括原始数据)和分子分析报告。指导委员会评估了原始数据和报告,并将其评论发送给每个实验室。结果:基因分型结果表明所有实验室的质量总体良好,即由于分析(45%)和曲解错误(45%)的错误,每年约有1%的等位基因被错误分配。在最初的两年中,超过70%的实验室未测试某些意大利区域性突变。用于反向斑点印迹和寡核苷酸连接测定PCR的商业试剂盒分别用于检测参与实验室的52.8%和29.5%的突变。结果报告仍然不足; 2004年,引入了书面报告的模型,但并非所有实验室都使用了该模型。结论:我们的数据表明实验室很少进行基因分型错误,主要是由于误解和分析原因。但是,报告仍然不足,因此在未来几年中评估报告模型的引入将很有趣。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号